N/A N=257 Mindfulness Mobile App to Reduce Adolescent Substance Use
Adolescent Drinking · Adolescent Problem Behavior
Primary: Number of Participants With Marijuana Use — 47; 40; 41; 41 Participants — p=.962
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=25 Imaging the Neurochemistry of Drug Addiction With PET
Smoking · Cannabis
Primary: Change in Dopamine Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images. — 0.0388; 0.033; 0.0285; 0.0368 mm^3
N/A N=105 Preventing Opioid Overdose Mortality in the United States
Opioid Overdose
Primary: Naloxone Coverage (Consistency) — 0.9; 0.4 proportion of participants — p=<0.01
N/A N=18 SmartHMD for Improved Mobility
Low Vision · Orientation · Mobility Limitation
Primary: Time-to-Complete — 14.75; 32.75; 148.17; 17.3 Seconds
N/A N=378 Connecting Resources for Urban Sexual Health
HIV · Sexually Transmitted Infections
Primary: The Proportion of Young Men Who Have Sex With Men (YMSM) Who Test Positive for HIV at Enrollment — 70; 28; 280 Participants
Phase 2 N=10 An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Tinnitus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 1 Participants
Phase 3 N=500 Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
Non-small-cell Lung Cancer
Primary: Estimated Overall Survival — 0.54; 0.56; 0.54; 0.56 proportion of participants — p=0.73
Phase 2 N=34 Extension Study in a Cohort of Adult Patients With COVID-19 Infection
COVID-19 Infection
Primary: Number and Percentage of Participants With Complications Related to Post COVID-19 Infection — 4; 8; 5; 17 Participants
N/A N=30 Prospective Clinical Study of the Levita Magnetics Surgical System Used for Prostatectomy Surgery
Prostatectomy
Primary: Number of Tools Required to Retract the Prostate During Procedure — 0 Additional Tools to Mobilize Liver
N/A N=56 Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil
HIV Infections · Tobacco Use Cessation
Primary: Number of Participants With a 7-day Prevalence Abstinence of Tobacco Use — 27 participants
Phase 3 N=77 Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
Duchenne Muscular Dystrophy
Primary: Change From Baseline in Time to Stand (TTSTAND) Velocity — 0.026; 0.013; 0.027; 0.014 rise/s
Phase 2 N=61 ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
Inflammatory Bowel Diseases · Clostridium Difficile Infection
Primary: Number of Participants With Clostridium Difficile Recurrence — 4; 1 Participants — p=0.15
N/A N=146 Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment
Scar · Skin Scarring · Skin Cancer
Primary: Cosmetic Outcome — 7.4; 6.6; 6.3; 6.00 score on a scale
Phase 1 N=44 Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
COVID-19
Primary: Number of Participants With at Least One Solicited Local Adverse Event (AE) Within 8 Days After the Injection of Prime Dose — 8; 6; 10; 10 Participants
N/A N=150 TPAP for Comfort in OSA
Obstructive Sleep Apnea
Primary: CPAP v TPAP Patient Preference at 9 cmH2O Baseline Pressure, TPAP Drop 2+2 cmH2O — 69.3 percentage of total participants